Siplizumab (Anti-CD2)
Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD.
Supplier | Selleck Chemicals |
---|---|
Product # | A2562 |
Sku # | A2562-1mg*5 |
Pricing | 1mg*5, $790.00 |